Archive · 6 Jan 2026
Dr. Reddy's Launches Hevaxin for Hepatitis E
Dr. Reddy's Laboratories has introduced a new vaccine called Hevaxin in India.
This vaccine is designed to protect adults aged 18 to 65 from Hepatitis E, a serious liver disease.
The vaccine has been approved by the Drug Controller General of India and has shown to be safe and effective in clinical studies.
Hepatitis E is a big problem in India, causing many cases of liver disease and deaths.
The vaccine will help in preventing this disease and support the government's program to control viral hepatitis.
Dr. Reddy's has partnered with other companies to market and distribute the vaccine in India.
Dr. Reddy's Laboratories launched Hevaxin, a recombinant vaccine for Hepatitis E in India.
Hevaxin is the only vaccine approved by DCGI for Hepatitis E prevention in adults aged 18-65.
Clinical studies show Hevaxin provides long-lasting immunity and has a favorable safety profile.
The vaccine supports the National Viral Hepatitis Control Programme to reduce Hepatitis E morbidity and mortality.
Dr. Reddy's partnered with Shenzhen Mellow Hope Pharm and Urihk Pharmaceutical for marketing and distribution.
- Who
- Dr. Reddy's Laboratories
- What
- Launched Hevaxin, a recombinant vaccine for Hepatitis E
- When
- January 6, 2026
- Where
- India
- Why
- To prevent Hepatitis E virus infection and support the National Viral Hepatitis Control Programme
- Company
- Dr. Reddy's Laboratories
- Vaccine Name
- Hevaxin
- Approval Authority
- Drug Controller General of India (DCGI)
- Target Age Group
- 18 to 65 years
- Global Hepatitis E Cases
- 20 million annually
- Global Deaths from Hepatitis E
- 70,000 annually
- India's Hepatitis E Cases
- 40% of acute hepatitis cases